Nimet ŞENOĞLU, Rıza Hakan ERBAY, Işıl KÖSE, Sibel ERSAN, Çiler ZİNCİRCİOĞLU, Hüseyin ÖZKARAKAŞ, Gürsel ERSAN, Şükran KÖSE

Risk factors for colistin-associated nephrotoxicity and mortality in critically ill patients

Background/aim: Colistin is gaining popularity against multidrug-resistant bacteria. The primary concern with colistin is its nephrotoxicity (NT). The aim of this study was to evaluate the incidence and risk factors for NT and to evaluate the risk factors for mortality in the toxicity group. Materials and methods: NT was defined according to the RIFLE criteria. Data of patients who did or did not develop NT were compared. Positive and negative predictive values, risk ratio, and correlation coefficients were calculated. Results: NT was seen in 39 patients (70%). Hypoalbuminemia, old age, and the use of vasopressors (VPs) were associated with NT. The use of VPs had the highest positive predictive value, while age had the highest negative predictive value and risk ratio. The only variable that was associated with mortality in the toxicity group was VP use. Conclusion: Aging, hypoalbuminemia, and the use of VPs were shown to be risk factors for NT, while the last of these was the only significant risk factor for mortality in the toxicity group.

PDF

___

1. Gaynes R, Edwards JR, for the National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. National Nosocomial Infection Surveillance System. Clin Infect Dis 2005; 41: 848-854.
2. Kunin CM. Nephrotoxicity of antibiotics. JAMA 1967; 202: 204-208.
3. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857-868.
4. Chang JW, Jeng MJ, Yang LY, Chen TJ, Chiang SC, Soong WJ, Wu KG, Lee YS, Wang HH, Tsai HL. The epidemiology and prognostic factors of mortality in critically ill children with acute kidney injury in Taiwan. Kidney Int 2015; 87: 632-639.
5. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DRJ, Dasbach EJ, Platt R. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2011; 32: 686-693.
6. De Mendonça A, Vincent JL, Suter PM, Moreno R, Dearden NM, Antonelli, M, Takala J, Sprung C, Cantraine F. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med 2000; 26: 915-921.
7. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly , Hamida CB, Chaari A, Rekik N, Bouaziz M. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007; 33: 1162-1167.
8. Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 2009; 34: 434-438.
9. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC: Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2010; 35: 297-300.
10. Sirijatuphat R, Limmahakhun S, Sirivatanauksorn V, Nation RL, Li J, Thamlikitkul V. Effect of ascorbic acid on colistinassociated nephrotoxicity: a preliminary clinical study. Antimicrob Agents Chemother 2015; AAC.00280-15.
11. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, Kapaskelis A, Nikita D, Michalopoulos A. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010; 35: 194-199.
12. Ko H, Jeon M, Choo E, Lee E, Kim T, Jun JB, Gil HW. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 2011; 117: c284-c288.
13. Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant gram-negative bacterial infections. Clin Microbiol Infect 2006; 12: 1227-1230.
14. Montero M, Horcajada JP, Sorli L, Alvarez-Lerma F, Grau S, Riu M, Sala M, Knobel H. Effectiveness and safety of colistin for the treatment of multidrug- resistant pseudomonas aeruginosa infections. Infection 2009; 37: 461-465.
15. Ouderkirk JP, Nord JA, Turett GS, Kislak JW: Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003; 47: 2659-2662.
16. Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 2012; 18: 1829.
17. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10: R27.
18. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute Dialysis Quality Initiative workgroup: acute renal failuredefinition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-R212.
19. Pike M, Saltiel E. Colistin-and polymyxin-induced nephrotoxicity focus on literature utilizing the RIFLE classification scheme of acute kidney injury. J Pharm Pract 2014; 27: 554-561.
20. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R et al. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-637.
21. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48: 1724-1728.
22. Kellum JA, Bellomo R, Ronco C. Definition and classification of acute kidney injury. Nephron Clin Pract 2008; 109: c182- 187.
23. Temocin F, Erdinc S, Tulek N, Demirelli M, Bulut C, Ertem G. Incidence and Risk Factors for Colistin-Associated Nephrotoxicity. Jpn J Infect Dis 2015; 68: 318-320.
24. Omrani AS, Alfahad WA, Shoukri MM, Baadani AM, Aldalbahi S, Almitwazi AA, Albarrak AM. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia. Ann Clin Microbiol Antimicrob 2015; 14: 1-6.
25. Gauthier TP, Wolowich WR, Reddy A, Cano E, Abbo L, Smith LB. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Ch 2012; 56: 2392-2396.
26. Sorli L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, Lerma FA, Knobel H, Benito N, Horcajada JP. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis 2013; 13: 380.
27. Doshi NM, Mount KL, Murphy CV. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy 2011; 31: 1257-1264.
28. Balkan II, Dogan M, Durdu B, Batirel A, Hakyemez IN, Cetin B, Karabay O, Gonen I, Ozkan AS, Uzun S et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis 2014; 46: 678-685.
29. Rocco M, Montini L, Alessandri E, Venditti M, Laderchi A, De Pascale G, Raponi G, Vitale M, Pietrapaoli P, Antonelli M. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care 2013; 17: R174.
30. Collins JM, Haynes K, Gallagher JC. Emergent renal dysfunction with colistin pharmacotherapy. Pharmacotherapy 2013; 33: 812-816.
31. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53: 879-884.
32. Kalin G, Alp E, Coskun R, Demiraslan H, Gündogan K, Doganay M. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator- associated pneumonia: do we really need this treatment? J Infect Chemother 2012; 18: 872-877.
33. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 2014; 43: 349-352.
34. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N. Highdose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012: 54: 1720-1726.
35. Binh NG, Hayakawa K, Co DX, Tuan ND, Anh NH, Thuy NTH, Phoung DM, Huong NT, Thuy PT, Chau NQ, et al. The efficacy and nephrotoxicity associated with colistin use in an intensive care unit in Vietnam: use of colistin in a population of lower body weight. Int J Infect Dis 2015; 35: 18-23.